



Every year approximately 800,000 people end their lives (World Health Organization, 2014). Mental health disorders have one of the strongest associations with suicide, with a systematic review of psychological autopsies finding 90% of suicide victims had a diagnosable mental health disorder at the time of their death (Cavanagh, Carson, Sharpe et al., 2003). Coroner’s records in Northern Ireland (NI) have revealed that at least 58% of individuals who took their own lives had been diagnosed with a mental health condition (O’Neill, Corry, Murphy et al., 2014). 

Psychotropic medications are a common treatment for mental disorders and numerous studies have highlighted their benefits in relation to suicidality. Antidepressants have led to less emergence or a reduction of suicidal thoughts or behaviours compared to placebo (Beasley et al., 2007; Gibbons, Brown, Hur et al., 2012; Montgomery, Dunner, & Dunbar, 1995; Verkes et al., 1998). Lithium, another psychotropic medication, used to treat bipolar disorder, also has a favourable reputation in reducing suicidality (Ahearn et al., 2013; Baldessarini et al., 2006; Cipriani, Hawton, Stockton, & Geddes, 2013; Collins & McFarland, 2008; Goodwin et al., 2003; Waern et al., 2002). In 2002, clozapine, an atypical antipsychotic, was the first psychiatric drug to be approved by the Food and Drug Administration (FDA) in the USA for the reduction of suicidal behaviour (Food and Drug Administration, 2002).

While these medications reduce the symptoms of mental disorders for many, queries have emerged with regards to their role in inducing or increasing suicidality in some individuals. The indications of a possible promoting effect of suicidality from antidepressants eventually led to action by drugs regulating bodies in the early 2000s, with both the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and the Food and Drug Administration (FDA) in the USA issuing warnings about induced suicidality with antidepressant use in children and adolescents. These warnings came after meta analyses, such as that by Wohlfarth and colleagues (2006), which analysed 22 paediatric antidepressant clinical trials and found increased suicidal events. Indeed recent studies continue to suggest that some psychotropic medications may induce suicidal ideation or behaviour (Sharma, Guski, Freund, & Gøtzsche, 2016; Sun, Lin, Lu, Hsu, & Kao, 2016). 

The adverse effects of medication on suicidality are not limited to psychotropic medications. The FDA has also issued warnings for varenicline, a drug used to help individuals stop smoking (Food and Drug Administration, 2009), atomoxetine, a drug primarily used for Attention Deficit Hyperactivity Disorder (ADHD) (Food and Drug Administration, 2005), and antiepileptic medications (Food and Drug Administration, 2008). Furthermore, it is logical to assume that the simultaneous use of numerous medications (polypharmacy) may confer a greater suicide risk in a number of ways such as increased side effects, greater potential for interactions between medications, and the use of prescribed medications in overdose. There is a dearth of studies examining polypharmacy in relation to suicidality, yet Lavigne and colleagues (2012) state “Studies of prescribing patterns leading up to suicide may identify markers of rising suicide risk that could be used to inform population-level screening and prevention…” (p. 565).

Studies looking at the links between medications and suicidality have included case reports, clinical trials, ecological studies and meta-analyses. Limitations of these methods include the inability to infer causation, the exclusion of those at risk of suicide in trials, confounding by mental health disorder, poly medication use, heterogeneous definitions and measurements of suicidality across studies, and the use of ideation and plans as surrogate outcomes for suicide. To deal with these methodological shortcomings, researchers have turned to toxicological and medical records of individuals who have died by suicide to study medication use in those who have taken their own lives.

Studies using medical records to understand use of medications by those who died by suicide have revealed that psychotropic medications have commonly been prescribed. Henriksson, Boëthius, & Isacsson (2001) found that of those who took their own lives, 17% had been prescribed hypnotics or anxiolytics and 7% had been prescribed antidepressants. More recently, the National Confidential Inquiry into Suicide and Homicide by People with Mental Illness (2014) found that almost half had been prescribed psychotropic medication in the 12 months prior to their suicide. Antidepressants were commonly prescribed; SSRIs 25%, TCAs 12%, and other antidepressants 12%. Benzodiazepines (19%) and other hypnotics and anxiolytics (14%) were also common.

Toxicological records have also been used to investigate use of medications by those who died by suicide. In addition to providing a more objective account of medication use given that individuals consumed the medications prior to death, by analysing alongside prescription medical records, toxicology details allow for issues such as adherence to be investigated. Medication non-adherence is a problem for those with mental disorders. A recent systematic review of antipsychotic adherence in those with schizophrenia and related disorders found that adherence ranged from 47.2% to 95% (Sendt, Tracy, & Bhattacharyya, 2015). A population survey in Canada found non-adherence rates of 45.9% for antidepressants, 38.1% for anxiolytics, 34.7% for sedatives/hypnotics, and 34.6% for antipsychotics (Bulloch & Patten, 2010). Meanwhile in their suicide sample, Isacsson and colleagues (1994) found no trace of antidepressants in over half of those who had been prescribed them.

Aims of the study







The sample for the study used records of suicide and undetermined intent, between 2005 and 2011, identified by the Coroners Service for Northern Ireland (CSNI). Ethical approval to collect data was obtained from the Office for Research Ethics Committees Northern Ireland (ORECNI) and Ulster University Research Ethics Committee.  

The Senior Coroner, along with a Research Associate, examined the undetermined deaths to identify probable suicides. These cases (n = 218) were then included alongside the previously established suicide verdicts to form the study sample (n = 1,668). Personnel from the Northern Ireland Statistics and Research Agency (NISRA) helped to ensure that suicide cases matched official government recorded suicide deaths. Several sources were used to obtain detailed information about the deceased including police reports, medical notes, and statements from next of kin. Due to the sensitive nature of the data, anonymity was preserved throughout. Physical and electronic access to the data was restricted.







In addition to sociodemographic variables, details relating to the suicide were also available from information contained within the coroner’s files. These included the method of suicide, adverse events prior to suicide and contents of suicide note (where available). 

Medical details
Medical details, including any existing medical conditions, service use prior to death, and the names of medications that had been prescribed, were provided by the General Practitioners (GPs) or doctors of the individuals after their death and recorded in the coroner’s physical files. These details were then extracted and recorded in an electronic database for further analysis. These details were the most current information available at the time of death. The prescription medications were then coded according to the British National Formulary (BNF), which classifies medications according to the system of the body upon which they act (Joint Formulary Committee, 2013). Medications were coded according to their typical licensed use. A number of medications had different purposes and fell into multiple BNF categories. The category of these medications was determined based upon individuals’ known medical conditions as well as the other medications they had been prescribed. In total, medications were coded into 23 different categories. These categories were then further divided into two groups: Physical health medications and mental health medications.

Toxicology screening





Latent Class Analysis (LCA) was used to identify underlying patterns in the medication data. The following medication categories were not included in the LCA due to low counts: Obesity, malignant disease/immunosuppression, eye, nutritional supplements, and psychostimulants. In the analysis several models are processed and compared using various fit statistics and criteria: the Akaike Information Criterion (AIC; (Akaike, 1987)), the Bayesian Information Criterion (BIC; (Schwarz, 1978)), Sample Size Adjusted Bayesian Information Criterion (SSABIC; (Sclove, 1987)), the Lo-Mendel-Rubin Likelihood Ratio Test (LMR-LRT; (Lo, Mendell, & Rubin, 2001)), and the entropy (Ramaswamy, Desarbo, Reibstein et al., 1993). Lower values on the AIC, the BIC, and the SSABIC indicate better model fit. When the p-value of the LMR-LRT reaches non-significance, it is suggested the model with one fewer class is accepted. Entropy provides an indication of how accurately the classes are clearly distinct, ranging from 0 to 1, a higher value indicates greater accuracy and classification. However, there are no stringent rules for model selection, rather theory and previous research findings in the area should be considered alongside these indices (Ram & Grimm, 2009).   







The prescription rates for the most common medications in the sample are presented in Table 1. Medication categories below 10% are not displayed. The majority of the sample (65.1%) had been prescribed at least one medication. Antidepressants were the most common medication, prescribed to 37.3%. Further analysis showed 4.5% of the sample had been prescribed a tricyclic antidepressant and 23% a selective serotonin reuptake inhibitor. Just over one quarter (28.2%) had been prescribed a hypnotic/anxiolytic medication. Just over half of the sample (51.7%) had been prescribed medication relating to a mental health disorder, with one fifth (20.2%) prescribed mental health medication exclusively. A smaller proportion of individuals (45.2%) had been prescribed medication for a physical condition, with 13.6% prescribed physical health medication exclusively. Almost one third (31.6%) of the sample had been prescribed medications for both mental and physical health conditions. 

Females were more likely than males to have been prescribed any medication (p < .001), with this difference evident for each of the specific medication groups investigated. Age differences were also evident, with a trend for older individuals more likely to have been prescribed each of the medication types. The majority of those aged 65 and over (91.2%) had been prescribed a medication prior to their suicide. However, there were variations in the types of medication prescribed, with the 50-64 year old age group rather than the oldest group of individuals most likely to have been prescribed antidepressants, analgesics and antipsychotics (p < .001). In terms of marital status, those who were married were more likely to have been prescribed cardiovascular and gastrointestinal medications only (both p < .05).

Females were more likely to have been prescribed a greater number of medications, with 46.3% prescribed three or more. There was also a trend for older individuals to have been prescribed a greater number of medications, with 53.9% of those aged 50-64 years old and 64% of those aged 65 years and older prescribed three or more medications. The median number of medications prescribed in the sample was one. 

As might be expected, antidepressants were included in many of the common medication combinations. These were taken exclusively by 8.5% of the sample, in conjunction with hypnotics/anxiolytics by 2.5% and alongside antipsychotics by 1.9%. Hypnotics/anxiolytics were used exclusively by 3.2% of the sample.

Of the individuals for which had toxicology screening had been conducted (n = 869), hypnotics and anxiolytics were the most common medication identified (25%). Antidepressants were identified in 18.4% of these cases, and analgesics in 16.2%. Just over half (57.4%) of those who had been prescribed antidepressants also had toxicology screening conducted. Excluding those who overdosed on a prescribed medication, in over half (62.1%) of these individuals, there was no trace of the antidepressant medication(s) they had been prescribed. Just over three in ten (36.7%) had a full match between their antidepressant prescription(s) and toxicology, while 1.3% had a partial match. For those prescribed hypnotics/anxiolytics, 62.2% had toxicology screening conducted. Excluding those who overdosed on a prescribed medication, again just over half (56.3%) had not taken the hypnotic/anxiolytic medication(s) they had been prescribed. Almost one third (30.7%) had a full match and 13% had a partial match. For those prescribed antipsychotics, 62.4% had toxicology screening conducted. Excluding those who overdosed on a prescribed medication, the prescribed antipsychotic(s) was not detected in 82.9%. Approximately one in five had a partial match (4.8%) or a full match (12.4%). 






Six models, one-class through to six-class were estimated. The six-class solution was rejected as the loglikelihood was not replicated even when model start values were increased. Table 2 displays the fit criteria for the remaining models. The AIC was lowest for the five class solution, the BIC was lowest for the three class solution while the four class solution had the lowest SSABIC value. Given that the BIC has been proposed as the superior fit statistic (Nylund, Asparouhov, & Muthén, 2007), that the LMR-LRT p-value became non-significant with the four class solution, and that the three class solution was more parsimonious and interpretable, the three class solution was accepted as the best fitting model. Entropy for the model was acceptable at 0.7.

Figure 1 shows the probability of being prescribed each of the medication categories for the three classes. One quarter of the sample (25.8%) was categorised into latent class 1. Class 1 had moderate probabilities of being prescribed various physical and mental health medications. Individuals in this class had an approximately 50% probability of being prescribed gastrointestinal, cardiovascular, hypnotic/anxiolytic, antidepressant, and analgesic medications. This class was therefore titled ‘mixed medication use’. Class 2 was the smallest class (17.7%). This class was characterised as having low probabilities (typically less than 10%) of being prescribed the majority of the medication types with the exception of antidepressants, antipsychotics and anxiolytic/hypnotics, which had probabilities of 0.745, 0.605, and 0.496 respectively. Class 2 was labelled as primarily mental health medication use. Over half of the sample (56.5%) were assigned to class 3. This was characterised by a low probability (< 0.2) of having been prescribed each of the medication types. This class was therefore labelled as low or baseline medication use.




















	Prescribing of medications was prevalent (65.1%) in this sample of individuals who died by suicide, and is almost identical to the rate of 64% of suicides prescribed medications reported by Henriksson and colleagues (Henriksson et al., 2001). The rate is slightly higher in comparison to studies in Sweden and Ireland which reported 46% and 48.6% of their samples had been prescribed medication (Departments of Public Health, 2001; Isacsson, Boëthius, & Bergman, 1992). This higher rate may be due to the time lapsed between studies, with evidence suggesting that medication use has increased over the years (Gu, Dillon, & Burt, 2010; Paulose-Ram, Safran, Jonas, et al., 2007). Over half (51.7%) of the individuals in the current study had been prescribed a psychotropic medication, compared with approximately one third in other studies (Departments of Public Health, 2001; Henriksson et al., 2001; Isacsson et al., 1992). This is in keeping with the higher rate of psychotropic medication use in the NI general population compared with other countries (Benson, O’Neill, Murphy et al., 2014). The dearth of recent studies examining medications in individuals who died by suicide makes it difficult to provide direct comparisons. The 51.7% mental health prescription rate is in alignment with the proportion of mental disorders (58%) reported in a separate study using the same dataset as the current study (O’Neill et al., 2014). While this suggests adequate treatment of mental disorders, the 58% mental disorder rate relates to diagnosed conditions only and therefore is likely to be an underestimate. Should the actual rate be closer to the typically reported rate of 90% in psychological autopsy studies (Cavanagh et al., 2003), this may represent undertreatment of mental disorders. 
	Similar to other studies, females in this study were more likely to use medication than males (Departments of Public Health, 2001; Manteuffel et al., 2014; Obermeyer et al., 2004). Older individuals are also more likely to use prescribed medications (Gu et al., 2010). Interestingly, those aged 25 to 34 years old, and not those under 25 years old as might be expected, were most likely to have been prescribed only one medication. They were also the group most likely to be prescribed an antidepressant only or a hypnotic/anxiolytic only. This is despite the fact that rates of mental disorders at the time of death increased with age in this sample (O’Neill et al., 2014). These findings could represent a reluctance in this age group to make repeat visits or to fully disclose their problems to prescribers. Primary care providers such as GPs should be aware of this pattern in this group of individuals.
	In terms of the medication categories, rates of anxiolytic/hypnotic and antipsychotic prescribing were similar to that of other studies with the rate of antidepressant prescribing higher.  While one cannot presume from prescription medication records that an individual had consumed their medication(s), toxicology analysis provided an objective record of medications used. Hypnotics and anxiolytics, rather than antidepressants, were the medication most often identified. This may reflect the greater likelihood of benzodiazepines to be used in overdose deaths compared with antidepressants (Jones, Mack, & Paulozzi, 2013). For those who had a toxicology screen conducted and had been prescribed antidepressants or hypnotics/anxiolytics, the non-adherence rates (those who had neither a partial nor full medication match) were 62.1% and 56.3% respectively. Four fifths (82.9%) of those who had been prescribed antipsychotics and had a toxicology screening conducted had not taken their prescribed antipsychotic medication. It is possible that some newer antipsychotics were not included in the toxicology assays, and therefore this rate represents an overestimate. However, the rate of 82.9% is in accord with antipsychotic adherence rates (Sendt et al., 2015). The rates of non-adherence for antidepressant and hypnotics/anxiolytics in the current study are in agreement with other suicide studies (Isacsson et al., 1994). Rather than focusing on the suicidality inducing side effects of medications, the current data suggests that non-adherence may be of greater concern. Given the association between mental disorders and suicide, it is logical to believe that non-adherence may lead to the exacerbation of symptoms and therefore the possibility of an individual taking their own life. Ruengorn and colleagues (2012) found in a cohort of patients with bipolar disorder that suicide attempts were almost four times more likely for those with poor medication adherence compared to those with good adherence, even after controlling for known suicide factors such as depression, number of previous attempts and stressful life events. Reasons for non-adherence in those with a mental disorder include efficacy and unpleasant side effects of medications as well as comorbidities (Chapman & Horne, 2013). Medical professionals should endeavour to monitor those using psychotropic medications to ensure they are using their medications appropriately. A good patient-practitioner relationship and engaging individuals with their medication treatment are key influences which may improve psychotropic medication adherence and lead to a reduction in suicides (Chaplin, 2007). 
The prescription of multiple medications was common, with one in three (30.7%) in the sample and almost half (46.3%) of females having been prescribed three or more medications. This compares with the rate of 11.2% found in a national study in Ireland (Departments of Public Health, 2001). Some studies have noted associations between the number of medications prescribed to individuals and suicidality (Gazalle et al., 2007; Youssef, 1990). It is probable that the number of medications prescribed is a proxy for the severity or number of disorders. The lack of a control population in the current study meant that a relationship between the number of prescribed medications and suicide could not be established. A national inquiry into suicide in those with mental disorders in England did compare prescribed medications with a control group and found an increased risk of suicide (National Confidential Inquiry into Suicide and Homicide by People with Mental Illness, 2014). When prescribing multiple medications, prescribers should be mindful of potential suicidality effects related to adverse drug interactions. The number of medications needed to treat disorders should be balanced with the potential for medications to be used in overdose. 
While over half of the sample (56.5%) was assigned to the baseline or low medication use class, 25.8% were in the mixed medication use class. This suggests that a quarter of individuals may have been suffering from both mental and physical conditions prior to their suicide. This is supported by O’Neill and colleagues (O’Neill et al., 2014) who reported one fifth (21.8%) of this sample had been diagnosed with both a mental and physical condition. While mental disorders are typically linked with suicide, physical disorders are also an important risk factor (Ilgen et al., 2013; Quan, Arboleda-Flórez, Fick et al., 2002). Rather than finding a distinct physical medication class, the LCA presented a mixed medications class. This is open to several interpretations. Suicidal individuals could be suffering from both mental and physical disorders. Or the physical problems could be manifestations of mental disorders, of which individuals are unaware. Regardless, primary care providers such as GPs should monitor those individuals who present with both physical and mental symptoms. The discovery of a mixed medications class also has implications for future research. Clinical trials looking at the effects of medication on suicidality typically focus on one medication type only, yet in this sample 2.5% had been prescribed an antidepressant alongside a hypnotic/anxiolytic and 1.9% an antidepressant alongside an antipsychotic. Future studies should either examine the combinations of medications linked to suicidality or control for concomitant use of other medications.

Strengths and limitations
This study was the first to provide a detailed analysis of the prescription of medications in a cohort of suicides in Northern Ireland. It was the first study to use LCA to examine combinations of medication use in those who died by suicide. Nevertheless, the study does have limitations. The lack of a control population for comparison limits the interpretation of associations between medications and suicide. Many other variables may have influenced the individuals in this sample to take their own lives. Data on prescribed medications was sourced from medical records and individuals’ GPs and doctors. This information was inconsistent and not available for all individuals and therefore the results may be biased. This bias would likely mean an underestimation of use for each of the medication categories. This echoes a limitation reported by O’Neill and colleagues (O’Neill et al., 2014) who reported missing data in this sample relating to medical diagnoses. Those involved in collating data relating to suicides in both NI and other countries should endeavour to obtain as much information as possible regarding the suicide and the deceased from relevant sources. 
There are several limitations in relation to the toxicology screening that should be considered in the interpretation of the results. The relative expense of screening in NI meant that its use was restricted to 52% of the current sample, many of which were cases where alcohol or other substances were thought to be involved in the death. Furthermore, those who had toxicology screening conducted differed in terms of age and marital status to those who did not. Drowning may have affected the results of the toxicology tests. Almost one in ten (7.9%) of the current sample died by drowning. The half-lives of medications must also be considered. Those medications with longer half-lives are more likely to have been identified in the toxicology screening results. 
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